Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Dec 19;16:17588359241307191. doi: 10.1177/17588359241307191

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), 2024

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 1. — Flow chart of the study design. Patients with LS-SCLC were screened according to established inclusion and exclusion criteria and divided into immune combined chemotherapy group (N = 34), immune combined chemoradiotherapy group (N = 26), and chemoradiotherapy group (N = 53) according to the treatment used. Survival information, prognostic factors, progression patterns, and safety of patients were also recorded and analyzed.

CT, chemotherapy; ECOG PS, Eastern Cooperative Oncology Group performance status; IO, immunotherapy; ir-AE, immune-related adverse event; LS-SCLC, limited-stage small-cell lung cancer; rr-AE, radiation-related adverse event; RT, radiotherapy; VALG, Veterans Administration Lung Study Group.